Browse > Article

Clinical and Clinicopathological Findings of Naturally Occurring Hyperadrenocorticism in Dogs: A Retrospective Study of 17 Cases  

Kang, Sang-Gil (DongSeoul Animal Hospital)
Yoo, Jong-Hyun (BK21 Program of Integrative Network Systems for Veterinarians in Basic Science, Industrial Animals and Preventive Medicines, Konkuk University)
Park, Chul (Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California)
Park, Hee-Myung (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
Publication Information
Journal of Veterinary Clinics / v.25, no.6, 2008 , pp. 476-481 More about this Journal
Abstract
A retrospective study of 17 dogs with hyperadrenocorticism (HAC) was performed to evaluate the clinical and clinicopathological outcomes in dogs with pituitary-dependent HAC or adrenal gland-dependent HAC. Sixteen dogs were monitored at day 10, 30 and 90 then every 3 month after first presentation. In each examination, physical examination and ACTH stimulation test and client questionnaire were performed. In 17 cases, eight dogs were successfully treated with mitotane therapy (median dose 16.7 mg/kg; range 5.3 to 50 mg/kg, SID); another one dog showed favorable response, but the clients declined to further treatment before the full control of the disease had been achieved; four dogs showed poor response to treatment. One dog was euthanized due to septicemia. These results showed canine HAC can be medically managed successfully without side effects at the doses used in this study.
Keywords
dog; hyperadrenocorticism; mitotane;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Kintzer PP, Peterson ME. Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms. J Am Vet Med Assoc 1994; 205: 54-61
2 Bertoy EH, Feldman EC, Nelson RW, Duesberg CA, Kass PH, Reid MH, Dublin AB. Magnetic resonance imaging of the brain in dogs with recently diagnosed but untreated pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc 1995; 206: 651-656
3 Duesberg CA, Feldman EC, Nelson RW, Bertoy EH, Dublin AB, Reid MH. Magnetic resonance imaging for diagnosis of pituitary macrotumors in dogs. J Am Vet Med Assoc 1995; 206: 657-662
4 Ford SL, Feldman EC, Nelson RW. Hyperadrenocorticism caused by bilateral adrenocortical neoplasia in dogs: four cases (1983-1988). J Am Vet Med Assoc 1993; 202: 789- 792
5 Forrester SD, Martínez NI, Panciera DL, Moon ML, Pickett CR, Ward DL. Absence of urinary tract infection in dogs with experimentally induced hyperadrenocorticism. Res Vet Sci 2003; 74: 179-182   DOI   ScienceOn
6 Neiger R, Ramsey I, O'Connor J, Hurley KJ, Mooney CT. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2002; 150: 799-804   DOI   ScienceOn
7 Nelson RW, Ihle SL, Feldman EC. Pituitary macroadenomas and macroadenocarcinomas in dogs treated with mitotane for pituitary-dependent hyperadrenocorticism: 13 cases (1981- 1986). J Am Vet Med Assoc 1989; 194: 1612-1617
8 Van Liew CH, Greco DS, Salman MD. Comparison of results of adrenocorticotropic hormone stimulation and lowdose dexamethasone suppression tests with necropsy findings in dogs: 81 cases (1985-1995). J Am Vet Med Assoc 1997; 211: 322-325
9 Feldman EC, Nelson RW, Feldman MS, Farver TB. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs. J Am Vet Med Assoc 1992; 200: 1642-1647
10 Forrester SD, Troy GC, Dalton MN, Huffman JW, Holtzman G. Retrospective evaluation of urinary tract infection in 42 dogs with hyperadrenocorticism or diabetes mellitus or both. J Vet Intern Med 1999; 13: 557-560   DOI
11 Ristic JM, Ramsey IK, Heath EM, Evans HJ, Herrtage ME. The use of 17-hydroxyprogesterone in the diagnosis of canine hyperadrenocorticism. J Vet Intern Med 2002; 16: 433-439   DOI
12 Ruckstuhl NS, Nett CS, Reusch CE. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 2002; 63: 506-512   DOI   ScienceOn
13 Behrend EN, Kemppainen RJ. Diagnosis of canine hyperadrenocorticism. Vet Clin North Am Small Anim Pract 2001; 31: 985-1003   DOI
14 Kipperman BS, Feldman EC, Dybdal NO, Nelson RW. Pituitary tumor size, neurologic signs, and relation to endocrine test results in dogs with pituitary-dependent hyperadrenocorticism: 43 cases (1980-1990). J Am Vet Med Assoc 1992; 201: 762-767
15 Rijnberk A, van Wees A, Mol JA. Assessment of two tests for the diagnosis of canine hyperadrenocorticism. Vet Rec 1988; 122: 178-180   DOI   ScienceOn
16 Barker EN, Campbell S, Tebb AJ, Neiger R, Herrtage ME, Reid SW, Ramsey IK. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitarydependent hyperadrenocorticism. J Vet Intern Med 2005; 19: 810-815   DOI
17 Norman EJ, Thompson H, Mooney CT. Dynamic adrenal function testing in eight dogs with hyperadrenocorticism associated with adrenocortical neoplasia. Vet Rec 1999;144: 551-554   DOI   ScienceOn
18 Chapman PS, Mooney CT, Ede J, Evans H, O'Connor J, Pfeiffer DU, Neiger R. Evaluation of the basal and postadrenocorticotrophic hormone serum concentrations of 17- hydroxyprogesterone for the diagnosis of hyperadrenocorticism in dogs. Vet Rec 2003; 153: 771-775
19 Bertoy EH, Feldman EC, Nelson RW, Dublin AB, Reid MH, Feldman MS. One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitarydependent hyperadrenocorticism. J Am Vet Med Assoc 1996; 208: 1268-1273
20 Saunders HM. Adrenal disease. Proceedings, 2nd International Symposium Vet Echography 1993; 31-34
21 Kintzer PP, Peterson ME. Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 1991; 5: 182-190   DOI
22 Wood FD, Pollard RE, Uerling MR, Feldman EC. Diagnostic imaging findings and endocrine test results in dogs with pituitary-dependent hyperadrenocorticism that did or did not have neurologic abnormalities: 157 cases (1989-2005). J Am Vet Med Assoc 2007; 231: 1081-1085   DOI   ScienceOn